These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 37888583)

  • 1. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
    Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
    Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
    Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions.
    Zhang G; Li J; Li G; Zhang J; Yang Z; Yang L; Jiang S; Wang J
    Clin Exp Med; 2024 Aug; 24(1):193. PubMed ID: 39141161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholangiocarcinoma - novel biological insights and therapeutic strategies.
    Ilyas SI; Affo S; Goyal L; Lamarca A; Sapisochin G; Yang JD; Gores GJ
    Nat Rev Clin Oncol; 2023 Jul; 20(7):470-486. PubMed ID: 37188899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers.
    Chen R; Zheng D; Li Q; Xu S; Ye C; Jiang Q; Yan F; Jia Y; Zhang X; Ruan J
    Cancer Lett; 2022 Oct; 546():215853. PubMed ID: 35921970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
    Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
    J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in Biliary Tract Cancers: Where Are We?
    Kalyan A; Khosla H; Kim RD
    Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma.
    Hua S; Gu X; Jin H; Zhang X; Liu Q; Yang J
    Biomed Pharmacother; 2024 Aug; 177():117080. PubMed ID: 38972151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting cholangiocarcinoma.
    Mertens JC; Ilyas SI; Gores GJ
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1454-1460. PubMed ID: 28844952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tertiary lymphoid structures predict the prognosis and immunotherapy response of cholangiocarcinoma.
    Shang T; Jiang T; Lu T; Wang H; Cui X; Pan Y; Xu M; Pei M; Ding Z; Feng X; Lin Y; Li X; Tan Y; Feng F; Dong H; Wang H; Dong L
    Front Immunol; 2023; 14():1166497. PubMed ID: 37234171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of Cholangiocarcinoma Immune Biology.
    Vita F; Olaizola I; Amato F; Rae C; Marco S; Banales JM; Braconi C
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in cholangiocarcinoma.
    Al-Rajabi R; Sun W
    Curr Opin Gastroenterol; 2021 Mar; 37(2):105-111. PubMed ID: 33507028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unveiling the immunogenomic landscape of cholangiocarcinoma: Identifying new prognostic markers and therapeutic targets based on CCL5 expression.
    Wang J; Xiang D; Dai Z; Zhu J; Du Y; Fu G; Chu X
    J Gene Med; 2024 Jan; 26(1):e3630. PubMed ID: 37985959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy and targeted therapy for cholangiocarcinoma: Artificial intelligence research in imaging.
    Liu J; Shu J
    Crit Rev Oncol Hematol; 2024 Feb; 194():104235. PubMed ID: 38220125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches.
    Vatankhah F; Salimi N; Khalaji A; Baradaran B
    Int Immunopharmacol; 2023 Jan; 114():109526. PubMed ID: 36481527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma.
    Zhang Y; Yan HJ; Wu J
    Curr Cancer Drug Targets; 2024; 24(7):681-700. PubMed ID: 38213139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts.
    Raggi C; Invernizzi P; Andersen JB
    J Hepatol; 2015 Jan; 62(1):198-207. PubMed ID: 25220250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?
    Wang J; Loeuillard E; Gores GJ; Ilyas SI
    Expert Opin Ther Targets; 2021 Oct; 25(10):835-845. PubMed ID: 34806500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment.
    Minini M; Fouassier L
    Curr Oncol; 2023 Apr; 30(4):4185-4196. PubMed ID: 37185432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.